CTOs on the Move

The District of Columbia Primary Care Associatio

www.dcpca.org

 
DCPCA is a nonprofit health reform organization founded in 1996 by health care professionals who were concerned that the shortage of primary health care in the District was contributing to increasingly poor health outcomes for DC's most vulnerable residents. With a budget of $140,000 in seed money from the federal government's Bureau of Primary Care, Sharon Baskerville became DCPCA's first executive director in 1998. As DCPCA established itself in the late 1990s, District voters elected a new mayor and six new members of the DC Council. The improved political environment made it possible for the District's budget to emerge from ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.dcpca.org
  • 1411 K St NW Ste 400
    Washington, DC USA 20005
  • Phone: 202.638.0252

Executives

Name Title Contact Details

Similar Companies

ENABLE Healthcare Communications

ENABLE Healthcare Communications is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synergetics USA, Inc

Synergetics USA, Inc. (Synergetics USA) designs, manufactures and markets microsurgical instruments, medical capital equipment and other medical devices primarily for use in ophthalmic surgery and neurosurgical applications.

Omega Protein

Omega Protein Corporation was a publicly traded US company, founded in 1913 as a fishing operation.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.

Fitzgerald Industries International

Fitzgerald Industries International is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.